Atopic dermatitis and skin diseaseGuselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Key words
Abbreviations used
Cited by (0)
Supported by Janssen Research & Development, LLC.
Disclosure of potential conflict of interest: H. Sofen has received consulting fees or honoraria from Janssen; was provided writing assistance, medicines, equipment, or administrative support from Janssen; and has received payment for lectures from Janssen, Amgen, Abbvie, Novartis, Pfizer, and Lilly. S. Smith has received research support from Janssen and has received payment for lectures from Janssen and Abbvie. R. T. Matheson has received research support from Janssen. C. L. Leonardi has consultant arrangements with Abbvie/Abbott, Amgen, Centocor/Janssen, Eli Lilly, Leo Pharmaceuticals, and Pfizer; has received payment for lectures from Amgen and Abbvie/Abbott; and has received fees for service for conducting clinical trials from Abbott, Amgen, Anacor, Celgene, Centocor/Janssen, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Maruho, Merck, Pfizer, Schering-Plough, Sirtris, Stiefel, Leo, Novartis, Tolmar, Novo Nordisk, Vascular Biogenics, Warner Chilcott, and Wyeth. C. Calderon, C. Brodmerkel, K. Li, K. Campbell, Y. Wasfi, Y. Wang, and P. Szapary are employed by Janssen (Johnson & Johnson) and have stock/stock options from Johnson & Johnson. S. J. Marciniak is employed by Janssen. J. Krueger has consultant arrangements with Pfizer, Centocor/Janssen, and Lilly and has received research support from Pfizer, Amgen, Centocor/Janssen, Lilly, and Merck.